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The results of the 'Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk' (FOURIER) study, the first completed cardiovascular outcome trial to examine the impact of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibition on cardiovascular events, has now been reported. 1 In this study, 27 564 patients with established atherosclerotic cardiovascular disease and LDL cholesterol levels > _70 mg/dL (1.8 mmol/L), despite optimized lipid-lowering therapy (mostly intense statin treatment) were randomized to treatment with evolocumab (a monoclonal antibody inhibiting PCSK9; either 140 mg every 2 weeks or 420 mg monthly) or matching placebo. A significant 59% reduction in LDL cholesterol levels was observed with evolocumab treatment when compared with placebo at 48 weeks from a median LDL cholesterol at baseline of 92 mg/dL (2.4 mmol/L) to 30 mg/dL (0.78 mmol/L). Importantly, during a median follow-up time of 26 months, a significantly reduced risk of cardiovascular events (in particular myocardial infarctions and strokes) was observed in patients treated with PCSK9 inhibition. , who worked on a class of enzymes known as proprotein convertases, reported the discovery of an enigmatic protein called neural apoptosis-regulated convertase 1 (NARC-1) that looked like a new member of the family. In the same year, two mutations in this newly discovered gene thought to lead to increased activity of PCSK9 were reported in French families with autosomal dominant familial hypercholesterolaemia. 3 In 2006, a study using sequence variants in PCSK9 reported association of these PCSK9 variants with reduced plasma levels of LDL cholesterol and a reduced incidence of coronary events. 4 These observations stimulated the rapid development of clinical study programmes to determine the efficacy of PCSK9 inhibition using monoclonal antibodies in lowering LDL cholesterol and the impact on cardiovascular events in patients with atherosclerotic cardiovascular disease. PCSK9 inhibition is now already used in clinical practice in patients with familial hypercholesterolaemia in need of additional LDL cholesterol-lowering approaches and in patients with severely increased cardiovascular risk. 5 Furthermore, other approaches to target PCSK9 are now in clinical development. In particular, a novel molecular approach is pursued to inhibit PCSK9 expression in the liver by RNA interference using a modified PCSK9 siRNA, where a Phase 2 study has recently been reported 6 and a Phase 3 clinical trial programme is planned.
These observations raise important scientific questions, e.g. about the role and implications of PCSK9 expression in non-hepatic cells. Although an important effect of PCSK9 inhibition is the increased availability of hepatic LDL receptors, effects of PCSK9 inhibition on other cell types and functions need to be further characterized. Moreover, the Prof. Ulf Landmesser is Chairman of the Department of Cardiology at Charité-Universit€ atsmedizin Berlin (Campus Benjamin Franklin) and BIH Professor of Cardiology (Berlin Institute of Health), Berlin, Germany. Landmesser works as an interventional cardiologist and his research team performs studies to better understand the pathophysiology of coronary disease and to examine novel approaches for prevention of adverse cardiovascular events.
